	US 12,404,541 B2
	Compositions and methods for detecting or quantifying human parainfluenza virus 2
Mehrdad Majlessi, Escondido, CA (US); Pamela Douglass, Kansas City, MO (US); and Daniel Kolk, Ramona, CA (US)
Assigned to GEN-PROBE INCORPORATED, San Diego, CA (US)
Filed by Gen-Probe Incorporated, San Diego, CA (US)
Filed on Feb. 15, 2024, as Appl. No. 18/442,644.
Application 18/442,644 is a division of application No. 17/072,890, filed on Oct. 16, 2020, granted, now 12,116,620.
Application 17/072,890 is a division of application No. 15/934,273, filed on Mar. 23, 2018, granted, now 10,844,425, issued on Nov. 24, 2020.
Claims priority of provisional application 62/476,435, filed on Mar. 24, 2017.
Prior Publication US 2024/0318231 A1, Sep. 26, 2024
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6811 (2018.01); C12Q 1/6816 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/6853 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6876 (2018.01); C12Q 1/6888 (2018.01); C12Q 1/70 (2006.01)

CPC C12Q 1/6811 (2013.01) [C12Q 1/6816 (2013.01); C12Q 1/6851 (2013.01); C12Q 1/6853 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6876 (2013.01); C12Q 1/6888 (2013.01); C12Q 1/701 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/166 (2013.01)]

22 Claims

1. A composition comprising at least a first HPIV-2 amplification oligomer and a second HPIV-2 amplification oligomer, wherein:

the first HPIV-2 amplification oligomer and second HPIV-2 amplification oligomer are configured to amplify an HPIV-2 target nucleic acid sequence of at least about 50 nucleotides in length comprising at least one HPIV-2 position located within HPIV-2 positions 1600-1700, wherein the first HPIV-2 amplification oligomer comprises the sequence of SEQ ID NO: 44, and

wherein the composition further comprises a third HPIV-2 oligomer configured to hybridize to the HPIV-2 target nucleic acid sequence, and the third oligomer comprises a chemiluminescent label or a fluorescent label.